非小细胞肺癌PD-(L)1阻断获得性耐药的基因组与免疫表型图谱
该研究对82例在Dana-Farber癌症研究所接受免疫检查点抑制剂(ICI)治疗后出现获得性耐药的非小细胞肺癌(NSCLC)患者的匹配前后活检样本进行基因组和免疫表型分析,并与化疗(N=32)、靶向治疗(N=89)及两者兼有(N=17)的对照组比较。发现27.8%的免疫治疗病例存在推定耐药突变,免疫表型显示瘤内淋巴细胞、CD3e+和CD8a+ T细胞及PD-L1-PD1结合显著减少,HLA-I类表达显著低于化疗组(P=0.005)和靶向治疗组(P=0.01)。
要点
- 27.8%的ICI治疗病例检出获得性功能丧失突变,涉及STK11、B2M、APC、MTOR、KEAP1和JAK1/2,对照组未见。
- ICI获得性耐药时瘤内淋巴细胞、CD3e+和CD8a+ T细胞及PD-L1-PD1结合显著减少,肿瘤细胞与CD8+PD-1+ T细胞间距增加。
- ICI组HLA-I类表达显著低于化疗组(P=0.005)和靶向治疗组(P=0.01)。
核心结论
- NSCLC中ICI获得性耐药存在基因组和免疫表型异质性,开发克服耐药的新策略时需加以考虑。
研究设计与样本
- 对82例在Dana-Farber癌症研究所接受ICI治疗后出现获得性耐药的NSCLC患者的匹配ICI前后肿瘤活检进行综合基因组分析、基于机器学习的肿瘤浸润淋巴细胞评估、多重免疫荧光和/或HLA-I免疫组化。
- 对照队列包括活检间接受化疗(N=32)、靶向治疗(N=89)及两者兼有(N=17)的患者。
主要发现
- 27.8%的免疫治疗病例检出推定耐药突变,包括STK11、B2M、APC、MTOR、KEAP1和JAK1/2的获得性功能丧失突变,对照组未观察到此获得性改变。
- 匹配ICI前后样本的免疫表型显示瘤内淋巴细胞、CD3e+和CD8a+ T细胞及PD-L1-PD1结合显著减少,肿瘤细胞与CD8+PD-1+ T细胞间距增加。
- ICI队列在获得性耐药时HLA-I类表达显著低于化疗队列(P=0.005)和靶向治疗队列(P=0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although immune checkpoint inhibitors (ICI) have extended survival in patients with non-small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI frequently develops after an initial benefit. However, the mechanisms of AR to ICI in NSCLC are largely unknown. METHODS: Comprehensive tumor genomic profiling, machine learning-based assessment of tumor-infiltrating lymphocytes, multiplexed immunofluorescence, and/or HLA-I immunohistochemistry (IHC) were performed on matched pre- and post-ICI tumor biopsies from patients with NSCLC treated with ICI at the Dana-Farber Cancer Institute who developed AR to ICI. Two additional cohorts of patients with intervening chemotherapy or targeted therapies between biopsies were included as controls. RESULTS: We performed comprehensive genomic profiling and immunophenotypic characterization on samples from 82 patients with NSCLC and matched pre- and post-ICI biopsies and compared findings with a control cohort of patients with non-ICI intervening therapies between biopsies (chemotherapy, N = 32; targeted therapies, N = 89; both, N = 17). Putative resistance mutations were identified in 27.8% of immunotherapy-treated cases and included acquired loss-of-function mutations in STK11, B2M, APC, MTOR, KEAP1, and JAK1/2; these acquired alterations were not observed in the control groups. Immunophenotyping of matched pre- and post-ICI samples demonstrated significant decreases in intratumoral lymphocytes, CD3e+ and CD8a+ T cells, and PD-L1-PD1 engagement, as well as increased distance between tumor cells and CD8+PD-1+ T cells. There was a significant decrease in HLA class I expression in the immunotherapy cohort at the time of AR compared with the chemotherapy (P = .005) and the targeted therapy (P = .01) cohorts. CONCLUSION: These findings highlight the genomic and immunophenotypic heterogeneity of ICI resistance in NSCLC, which will need to be considered when developing novel therapeutic strategies aimed at overcoming resistance.
引用
- Ricciuti B, Lamberti G, Puchala SR, et al. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. J Clin Oncol. 2024. PMID: 38207230. doi:10.1200/JCO.23.00580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。